MESO — Mesoblast Limited
Is MESO overbought or oversold? Here is the current MarketMoodz read.
Mesoblast Limited (MESO) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $12.45. The rating moved from Oversold to Strong Oversold on November 16, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$12.45
- Last changeMoved from Oversold to Strong Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Mesoblast Limited (MESO) is a clinical-stage cell-therapy company with a differentiated allogeneic platform and several program-level catalysts expected over the coming weeks and months. Financially, the company appears dependent on external capital or partnerships to advance late-stage development and commercial readiness, which elevates dilution and funding risk in a cautious macro environment. Near-term upside will hinge on positive clinical/regulatory updates or strategic collaborations, while downside is driven by trial, regulatory, manufacturing, and reimbursement uncertainties.
Key factors
- Clinical-stage allogeneic cell therapy platform with potential indications in inflammatory and cardiology areas
- Upcoming clinical readouts and regulatory milestones expected to drive near-term share activity
- Limited or uneven near-term commercial revenue; company likely reliant on capital markets or partnerships to fund operations
- Partnership and licensing optionality with larger pharma could de-risk development and provide milestone/royalty upside
- Niche positioning with potential first-mover advantages in specific cell-therapy niches but also technological and manufacturing complexity
- Macro funding environment and cautious market tone could constrain small-cap biotech financing and secondary issuance pricing
- Limited public sentiment and EDGAR insights in the provided window reduce near-term informational catalysts
Risks
- Clinical trial failures or negative efficacy/safety readouts that would materially reduce value of the pipeline
- Regulatory setbacks or delays in approvals leading to prolonged development timelines and higher cash burn
- Need for additional capital through equity dilution or expensive debt, which can depress existing shareholder value
- Manufacturing scale-up and quality control challenges specific to allogeneic cell therapies
- Reimbursement, payer access and commercial adoption hurdles even if regulatory approval is achieved
- Competition from other cell therapies, biologics and emerging modalities targeting similar indications
- Low liquidity and high share price volatility that can exacerbate downside on adverse news
See today's live rating, score and targets
Members see the live hourly rating for MESO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.